Articles tagged with Brain Tumors
Researchers have designed a drug called MP-MUS that targets the energy source of brain tumor cells, crippling their ability to grow and divide. In animal models and human tissue cultures, MP-MUS destroyed 90-95% of malignant glioma cells without affecting healthy brain cells.
Researchers at the University of Texas Health Science Center at San Antonio have launched a groundbreaking clinical trial using tiny radioactive liposomes to treat brain cancer. The technology has shown promising results with minimal side effects in the first patient, and the team expects to start the second patient soon.
Researchers have discovered that slow-growing brain cancer stem cells are resistant to treatment and can survive stress by producing a protein called Abcg1. The study suggests that using different drugs and higher dosages may be necessary to target these treatment-resistant stem cells.
A tetanus booster enhances immune system priming for dendritic cell therapy, increasing patient survival by nearly five years. The study provides a roadmap for improving dendritic cell vaccines for glioblastoma treatment.
A phase II study shows patients with high-risk low-grade gliomas have a 73% three-year overall survival rate when treated with radiation and temozolomide, compared to 54% for historical controls. The findings suggest combining chemotherapy with radiation is the best treatment for these rare tumors.
Northeastern researchers have found that supplemental oxygenation can shrink tumors and improve cancer immunotherapy by inhibiting hypoxia-driven adenosine accumulation and weakening immunosuppression. This approach has the potential to increase survival rates of patients with cancer, which kills over 8 million people annually.
A new study has found that brain tumor patients with private insurance have shorter hospital stays, fewer medical complications, and a lower risk of death compared to those without. In contrast, Medicaid patients are more likely to experience longer hospital stays, develop postoperative respiratory issues, and face higher risks of hosp...
A new study by University of Florida Health researchers found that brain tumor patients with private insurance have shorter hospital stays and fewer medical complications compared to those without insurance. They are also at lower risk of developing new conditions and dying during their stay.
Researchers at Moffitt Cancer Center have identified a key protein signaling pathway involved in the growth and survival of brain tumor stem cells. The neurotrophin pathway controls nerve growth, survival and specialization, and inhibiting TrkB and TrkC receptors can decrease stem cell survival.
Researchers at Tel Aviv University have developed a groundbreaking strategy to stop brain tumor cell proliferation with targeted nanoparticles. The therapy uses RNA genetic interference to silence key proteins involved in cell division, resulting in promising survival rates for mouse models.
Researchers at Johns Hopkins Medicine have discovered a genetic pathway that regulates thousands of genes and may fuel cancer cell growth. Blocking this pathway with the experimental drug selumetinib led to reduced tumor growth and increased cell death, offering new hope for aggressive pediatric brain cancer treatment.
A new test, PLA test, evaluates the effectiveness of cancer vaccines by detecting tumor antigens presented on MHC molecules. The test has shown promising results in identifying glioma tumors and melanoma cells with specific antigens.
A novel, non-invasive treatment strategy for Cushing Disease has been discovered using silibinin from milk thistle seeds. The active compound binds to heat shock protein 90, allowing glucocorticoid receptor molecules to dissolve and restore normal ACTH production.
Researchers found salicylates reduce vestibular schwannoma cell viability and proliferation without affecting healthy nerve cells. The study's results suggest salicylates as promising pharmacotherapies against vestibular schwannomas, which can cause hearing loss and tinnitus.
Two new fluorescent dyes, CLR1501 and CLR1502, attracted to cancer cells, were evaluated for their ability to differentiate brain tumors from normal brain tissue in mice. The results confirmed that both agents provided excellent fluorescence discrimination of tumor from adjacent normal brain.
Research found a statistically significant association between long-term hormonal contraceptive use and glioma risk in women aged 15-49. The study suggests that taking hormonal contraceptives for at least five years may increase the risk of developing a rare brain tumor, glioma.
Researchers at Penn Medicine have discovered a mutated ATRX gene as a potential biomarker for aggressive brain tumors and rare adrenal tumors. The study found that 13% of tumors had ATRX mutations, which were more common in clinically aggressive cases.
A novel imaging technique called restriction spectrum imaging-MRI (RSI-MRI) has been developed to improve the accuracy of prostate cancer detection. RSI-MRI corrects for magnetic field distortions and focuses on water diffusion within tumor cells, providing a more refined sense of the tumor's extent.
Recent guidelines aiming to reduce neuroimaging tests for patients with headaches may overlook diagnoses of brain tumors. Neurosurgeons warn that these limits could delay or even prevent diagnosis in up to 30% of cases, leading to delayed treatment and poorer outcomes.
Researchers discovered specific genetic paths that medulloblastoma follows when it relapses, identifying potential subsets of patients treatable with existing drugs. The study suggests taking additional tumor samples at recurrence could lead to more effective treatments.
A new statistical model developed by WPI's Patrick Flaherty allows better identification of different cell types found in solid tumors, enabling more targeted treatment options. The GLAD model accurately predicted the fractions of various subtypes in glioblastoma tumors and has potential applications in breast cancer treatment.
Researchers at the University of Rochester used imaging technique to show how brain heals itself after surgery, predicting vision recovery based on myelin insulation. This finding could have implications for treating various central nervous system injuries.
ANG4043 shows therapeutic brain concentrations in healthy mice and in mice bearing intracranial HER2+ tumors, increasing median survival time by 78% in a HER2+ intracranial tumor model. This technology has the potential to create brain-penetrant mAbs for treating neurological diseases.
Researchers have identified a gene associated with familial glioma, suggesting that certain individuals may be genetically predisposed to the disease. The POT1 gene mutation is linked to lower-grade oligodendroglioma, which is more sensitive to radiation therapy, and raises hopes for improved treatments and preventive strategies.
A new study has identified the SUFU gene mutation as a major contributor to Gorlin syndrome-associated childhood medulloblastoma, significantly increasing the risk of brain tumors in children with this condition. This finding has major implications for treatment and screening protocols for children with Gorlin syndrome.
A study by MD Anderson Cancer Center researchers found that the enzyme PKM2 controls cell division, promoting tumor cell proliferation. PKM2's role in regulating cytokinesis was also identified as crucial for brain tumor development and malignant tumor progression.
Researchers at Northwestern University have discovered a potential drug therapy for a rare, incurable pediatric brain tumor by targeting a genetic mutation. The experimental drug GSKJ4 delayed tumor growth and prolonged survival in mice with diffuse intrinsic pontine glioma (DIPG).
Researchers have solved a decades-old mystery by uncovering the formation of massive DNA molecules, dubbed 'neochromosomes', in some tumours. These giant chromosomes are formed through catastrophic chromosomal shattering and genetic amplification, ensuring the cancer's survival.
A Loyola University Medical Center study has found radiation to be a risk factor for the development of meningiomas, a type of brain tumor, in individuals under age 30. The study analyzed records of patients diagnosed with meningiomas before age 30 and found that five had been exposed to ionizing radiation earlier in their lives.
Researchers have identified the normal function of the TEM5 protein, which is crucial for embryonic blood vessel development. The findings suggest that TEM5 could be a good target for anticancer drug therapy and potentially improve drug treatment for brain diseases by temporarily disabling the blood-brain barrier.
Researchers at Case Western Reserve University have been awarded a $250,000 grant to study the use of nanotechnology in treating pediatric glioma brain tumors. The team aims to develop targeted and less toxic treatment strategies for this devastating disease.
Harvard Stem Cell Institute scientists have developed a way to use stem cells in the fight against brain cancer. They genetically engineered stem cells to produce and secrete tumor-killing toxins, which were shown to kill cancer cells in mouse brains. This method solves the delivery issue that led to previous clinical trial failures.
A study published in the Journal of Clinical Endocrinology & Metabolism found that mutations in the ARMC5 gene promote the growth of benign tumors in the adrenal glands and meninges. This discovery provides new insights into the causes of Cushing's syndrome, a disease characterized by elevated cortisol levels.
Researchers at the University of Montreal discovered that Sonic Hedgehog promotes medulloblastoma progression by inducing DNA damage. Inactivation of Boc receptor reduces tumour growth and progression.
Researchers have discovered a fusion protein in approximately 15% of secondary glioblastomas, offering insights into the disease's cause and potential therapeutic targets. The PTPRZ-MET fusion may be exquisitely sensitive to existing MET inhibitors, allowing for personalized oncologic care.
A CTRC doctor has been awarded a $1.6 million FDA orphan grant to study the efficacy of TH-302 in treating glioblastoma, a devastating brain tumor with a median survival time of four months. The drug, combined with Avastin, aims to slow tumor growth by creating a low-oxygen environment, sparing healthy cells from chemotherapy damage.
Researchers at IRCM discovered that a protein called Sonic Hedgehog induces DNA damage, which promotes the progression of medulloblastoma, the most common brain tumor found in children. The study found that Boc receptor is required for Sonic Hedgehog to induce DNA mutations, reducing tumour growth by 66%.
Researchers have identified the interleukin-13 receptor ¬ chain variant 2 (IL13R¢) as a potential target for therapy in glioblastoma multiforme (GBM). Early successes of clinical trials with targeted therapies against IL13R¢ suggest increased survival time for GBM patients.
Researchers found that adding rapamycin to an immunotherapy approach strengthened the immune response against brain tumor cells, increasing the effect of new therapies. The study also showed increased memory cells, allowing the immune system to attack tumors more effectively.
Researchers developed a new method to detect malignant brain tumors using a handheld Raman scanner, which can identify cancerous cells with high accuracy. The technique has the potential to improve surgical outcomes and reduce tumor recurrence rates.
The new program uses a statistical model to accurately predict IDH1 mutation likelihood and requires only four questions from healthcare providers. The app aims to conserve research dollars by helping researchers narrow down which tumors should be tested as data.
A modified version of Clostridium novyi bacterium has been shown to produce a strong anti-tumor response in rats, dogs and now humans. The treatment involves direct injection of spores into tumors, targeting oxygen-starved cells while sparing healthy tissue.
Brain tumors grow exclusively within narrow spaces between and along the brain's thousands of small blood vessels, contrary to the theory of neoangiogenesis. This 'autovascular' growth allows tumor cells to draw energy and fuel their growth like normal brain tissue.
Researchers have discovered a way to induce immunorejection of tumors formed by stem cell transplantation, potentially eliminating cancer. The study used laboratory mice and found that withdrawal of immunosuppression led to rejection of tumors, creating a 'safety lock' against tumor growth.
A new triple therapy combining two immunotherapies and targeted radiation has prolonged the survival of mice with glioblastoma brain cancer by up to 67 days. The treatment induces an immune response against tumors, creating long-term immunity.
A study found that retinoblastoma protein is less active in male brain cells, leading to higher brain tumor rates and poorer survival rates. The researchers believe this discovery could lead to more effective therapies and treatments.
Researchers have yet to identify a specific cause or risk factor for brain tumors, but ionizing radiation is recognized as a risk factor in therapeutic doses. Recent studies have ruled out associations between brain tumors and cell phone use, cigarette smoking, or other environmental factors.
A Cincinnati Cancer Center study finds that SapC-DOPS, a combination of lysosomal protein saposin C and phospholipid DOPS, targets and kills cancer cells, including those from breast and lung cancers. The treatment showed promise in animal models, with some tumors completely cured within 24 hours.
Researchers at the University of Texas Health Science Center at San Antonio have discovered that capsazepine can shrink oral cancers while leaving healthy tissues intact. The study's findings suggest that capsazepine may reduce oral cancer pain by blocking tumor-secreted factors from stimulating pain-sensing neurons.
Researchers identified a core signalling system, the hippo pathway, and discovered how Merlin suppresses it within the nucleus. This understanding paves the way for developing effective drug therapies to treat nervous system tumours.
Researchers have discovered that invading glioblastoma cells hijack cerebral blood vessels to extract nutrients, damaging the brain's protective barrier and potentially leading to new cancer treatments. This finding could enable earlier delivery of anti-invasive agents to attack tumor cells.
A Purdue-designed tool uses mass spectrometry to analyze brain tumor tissue, providing color-coded images that reveal the location and nature of tumor cells. The tool has been successfully used in two surgical procedures, offering a significant improvement over current methods.
Researchers are drawing attention to the rare disease due to its misdiagnosis. Caused by small benign tumors in the pituitary gland, it can lead to excessive weight gain, acne, and a lump on the back of the neck.
A collaborative study has identified two oncogenes, GFI1 and GFI1B, that drive the development of medulloblastoma, the most common malignant brain tumor in children. The findings suggest these genes are worthy candidates for molecular-targeted therapy.
Scientists at EMBL and DKFZ identified two sister genes, GFI1B and GFI1, as major drivers of Group 3 medulloblastoma. Large-scale DNA rearrangements relocate these genes, activating them and driving tumour formation.
The study reveals that each glioblastoma tumor contains individual cells from multiple cancer sub-types, and that the distribution of these cells varies from tumor to tumor. This heterogeneity may contribute to drug resistance and disease recurrence, highlighting the need for personalized treatment approaches.
Researchers at Duke University Medical Center have identified a genetic mutation in PPM1D that contributes to the growth and death of tumor cells in brainstem glioma. This mutation may render radiation therapy ineffective, providing immediate clinical benefits and paving the way for new drug development.
A research team at UT Southwestern Medical Center has identified the triggering mechanism of an atypical metabolic pathway that allows certain cancerous tumors to thrive. The discovery could provide a future target for drugs that would attack tumors relying on this reverse pathway for sustenance and growth.
Researchers developed herpes-loaded stem cells that significantly improved survival rates in mice with glioblastoma multiforme when applied to tumors. The treatment used mesenchymal stem cells as drug delivery vehicles, allowing oncolytic viruses to replicate and kill residual cancer cells.
Researchers have developed a new imaging technology using SapC-DOPS to visualize brain tumors, which could lead to improved treatment options for patients. The technique delivers bio-fluorescence agents and contrast agents directly to tumors, providing valuable information for diagnosis and treatment decisions.